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“ Não sou nada. Nunca serei nada. Não 
posso querer ser nada. À parte isso, 
tenho em mim todos os sonhos do 
mundo.” 
Álvaro de Campos, Tabacaria 
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Resumo 
Os tumores neuroendócrinos gastroenteropancreáticos (GEP-NETs) constituem um grupo 
heterogéneo e invulgar de neoplasias que sofreu um aumento exponencial da sua 
incidência e prevalência nas últimas décadas. Em paralelo com o aumento da taxa de GEP-
NETs, obesidade, síndrome metabólica (SM) e diabetes também são dos principais 
problemas clínicos e de saúde pública em crescimento a nível mundial. A associação entre 
SM, os seus parâmetros e cancro foi recentemente mostradas para diferentes tipos de 
neoplasias, contudo a sua associação com os GEP-NETs ainda não foi reportada e merece 
ser explorada. O objetivo deste estudo foi avaliar a influência da SM e dos seus parâmetros 
individuais na expressão de diferentes marcadores moleculares que participam em vias 
metabólicas e inflamatórias em GEP-NETs e tecido peri-tumoral, bem como correlaciona-
las com as características clinicas e patológicas do tumor. Com este objetivo, foram 
efetuadas análises imunohistoquímicas para avaliar a presença de IL-6, FOXM1 e IGF1R 
em cortes de GEP-NETs embebidos em parafina (n= 39) seguido por uma análise 
morfométrica para determinar a percentagem de área marcada no tumor (Ki-67, FOXM1 e 
IGF1R) e tecido peri-tumoral (IL-6). O presente estudo mostrou que a expressão de Ki-67, 
FOXM1 e IGF1R nos GEP-NETs não foi significativamente diferente na presença ou 
ausência de SM ou algum dos seus parâmetros. Porém, foi observada uma correlação 
positiva e significativa entre o Ki-67 e FOXM1 em NETs pancreáticos e ainda uma 
correlação positiva e significativa entre o FOXM1 e IGF1R em NETs gastrointestinais. A 
expressão do IL-6 no tecido peri-tumoral de NETs pancreáticos foi significativamente 
menor em doentes com obesidade central e em NETs gastrointestinais foi 
significativamente maior em doentes com HDL baixo. Não se observaram diferenças 
significativas de expressão do IL-6 na presença ou ausências de SM ou qualquer um dos 
seus outros parâmetros. Estes resultados sugerem que a presença da SM ou de algum 
dos seus parâmetros individuais não influencia significativamente nenhum dos marcadores 
estudados e assim alguma das vias com os quais estão relacionados nos GEP-NETs, 
exceto para o IL-6. Nos NETs gastrointestinais a expressão do IL-6 sugere que um baixo 
HDL pode contribuir para um microambiente inflamatório na área peri-tumoral. Por sua vez, 
o FOXM1 e a sua via parecem estar envolvidos na proliferação celular em GEP-NETs e a 
sua inibição poderá ser um alvo molecular importante para o tratamento destes tumores. 
Para além disso, os resultados sugerem que a expressão e atividade do FOXM1 em NETs 
gastrointestinais possa estar relacionada com a atividade do IGF1R. Estudos futuros serão 
necessários para perceber a associação e influência da SM e dos seus parâmetros 
individuais nos GEP-NETs e ainda para avaliar e compreender o potencial do FOXM1 e 
IGF1R como possíveis alvos no tratamento de GEP-NETs.           
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Abstract  
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) comprise an uncommon and 
heterogeneous group of neoplasms which had an exponential increase in terms of 
incidence and prevalence throughout the last decades. In parallel with the increasing rate 
of GEP-NETs, obesity, metabolic syndrome (MS) and diabetes are also major and 
escalating public-health and clinical problems worldwide. The link between MS, its 
parameters and cancer has been recently demonstrated for several types of neoplasia, 
however the association with GEP-NETs has not so far been reported, although it deserves 
to be explored. The objective of this study was to evaluate the influence of MS criteria and 
their individual parameters in the expression of different molecular markers that participate 
in metabolic and inflammatory pathways in GEP-NETs and peri-tumoral tissue, as well as, 
their correlation with the tumor clinical and pathologic features. To achieve this aim, 
individual immunohistochemical studies for the presence of IL-6, FOXM1 and IGF1R were 
performed in sections of paraffin-embedded GEP-NETs tissue (n= 39) followed by an 
morphometric computerized analysis tool in order to assess the percentage of stained area 
in the both tumor (Ki-67, FOXM1 and IGF1R) and peri-tumoral (IL-6) area. The present 
study has shown that Ki-67, FOXM1 and IGF1R expression in pancreatic and 
gastrointestinal NETs was not significantly different between patients with or without MS or 
any of MS individual parameters. A significant positive correlation between the Ki-67 and 
FOXM1 expression in pancreatic and gastrointestinal NETs was observed, as well as, a 
significant positive correlation between the FOXM1 and IGF1R expression in 
gastrointestinal NETs. IL-6 expression at the peri-tumoral area in pancreatic NETs was 
significantly lower in patients with central obesity and significantly higher in gastrointestinal 
NETs of patients with low HDL. IL-6 expression in the peri-tumoral tissue was not found to 
be significantly different between patients with or without MS or any other of the reminder 
MS individual parameters in GEP-NETs. These results suggest that the presence of MS or 
any of its individual parameters does not significantly influences any of the studied markers 
and thus related pathways in GEP-NETs, except for IL-6. IL-6 expression at the peri-tumoral 
area of gastrointestinal NETs suggest that low HDL in gastrointestinal NETs may contribute 
to the inflammatory environment in the peri-tumoral area. FOXM1 and its pathway might be 
involved in GEP-NETs cell proliferation and thus FOXM1 inhibition could be an important 
molecular target for GEP-NETs treatment. Furthermore, the results suggest that FOXM1 
expression could be stimulated and activated by IGF1R activity or vice-versa in 
gastrointestinal NETs. Future studies will be required in order to understand the link and 
influence of MS criteria, its individual parameters with GEP-NETs and to assess and 
understand the potential of FOXM1 and IGF1R as possible GEP-NETs treatment targets. 
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Chapter 1- Introduction 
1.1- Neuroendocrine Tumors 
Neuroendocrine tumors (NETs) originate from neuroendocrine (NE) cells that can be found 
throughout the body and comprise a heterogeneous group of unusual neoplasms 
characterized by a common neuroectodermal embryological origin and different biological 
behavior (Pusceddu et al., 2015; Singh & Law, 2012; Xiaojiang Yi, 2013; Yao et al., 2008). 
NE cells, share features of neural and endocrine differentiation, belong to the diffuse 
endocrine system and are present in certain organs and glands, such as the thyroid, 
pancreas and adrenals, as well as, throughout the body, including the vascular system, 
respiratory tract and the gastrointestinal mucosa (Essand et al., 2011; Rindi & Wiedenmann, 
2011; Uccella, Sessa, & Rosa, 2015). Regardless of their location, NETs share familiar 
biochemical features. These neoplastic cells present secretory granules, synaptic-like 
vesicles and assemble precursor molecules which are then processed and capable of 
producing hormones, peptides or amines (Essand et al., 2011; Rindi & Wiedenmann, 2011; 
Uccella, Sessa, & Rosa, 2015). Despite some resemblances, accordingly with their location 
in the human body these cells diverge in their tightly controlled ability to secrete and release 
hormones into the blood stream, adjacent cells or neurons and regulate various specific 
processes, such as, air flow, gastrointestinal secretion, blood pressure and motility (Andrew, 
Kramer, & Rawdon, 1998; Essand et al., 2011). NE differentiation can be found in many 
human neoplasms, such as colorectal and prostate cancer, and has been suggested as a 
marker of poor prognosis for a variety of carcinomas, having the ability to uptake/set free 
different NE substances (Parimi, Goyal, Poropatich, & J Yang, 2014; Rindi & Wiedenmann, 
2011; Sun, 2004). 
These uncommon and heterogeneous groups of epithelial neoplasms originate in various 
anatomic locations, but are most prevalent in certain organs, such as lungs, stomach, 
appendix, cecum, duodenum, pancreas, jejunum/ileum, colon, and rectum, or they are 
diffused throughout the body, comprising nearly 0.49% of all malignancies (Fraenkel, 
Faggiano, & Valk, 2015; Singh & Law, 2012; Xiaojiang Yi, 2013). It is described that, two 
thirds of NETs arise and are detected in the gastroenteropancreatic system (Uccella, Sessa, 
& Rosa, 2015). Independently of their primary site and of their degree of differentiation, the 
incidence of NETs, currently estimated to be of 5.53/100,000 people/year for males and 
4.76/100,000 people/year for females, has increased significantly in the last 30 years 
(Pusceddu et al., 2015). 
NETs classification has been constantly evolving during the last decades. Nowadays, NETs 
comprise a broad spectrum of potentially malignant diseases spanning from rather benign 
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to very malignant and lethal variants, and many of them present hormonal syndromes and 
are highly vascularized solid tumors (Giandomenico, Thirlwell, & Essand, 2015; Uccella, 
Sessa, & Rosa, 2015; Yao et al., 2008). In the meanwhile, the understanding of NETs 
biology and treatment through different approaches based in exploring genetics, molecular 
pathways, molecular targets and potential novel biomarkers has changed dramatically in 
the last decade (Giandomenico, Thirlwell, & Essand, 2015). Latterly, one of the major 
limitations to overcome these malignancies relates to diversity in the mechanisms 
underlying the molecular pathogenesis of NETs. In cancer cells the signaling networks that 
tightly control the major cellular activities, such as proliferation, differentiation, apoptosis 
and survival are deregulated (Giandomenico, Thirlwell, & Essand, 2015). Regardless the 
current awareness, NETs diagnosis based on clinical symptoms, laboratory measurement 
of secretory hormones and peptides, radiologic and nuclear imaging, and histology, is often 
challenging (Singh & Law, 2012). Nevertheless, the knowledge of NETs biology has been 
going through a real revolution where new findings about specific molecular events have 
led to the development of novel molecular-targeted therapies against different targets that 
might become a feasible and better treatment alternative (Giandomenico, Thirlwell, & 
Essand, 2015). Despite all the progress in the knowledge about NETs biology there is a 
long way to unravel the key mechanisms for tumor progression.  
 
1.2- Gastroenteropancreatic neuroendocrine tumors 
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) comprise a group of rare and 
heterogeneous neoplasms that emerge from enterochromaffin epithelial cells of the diffuse 
endocrine system sparse throughout the mucosa of gastrointestinal tract and pancreas 
(Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014). These 
cells share the structure and functional traits of the NE phenotype and have a wide spectrum 
of clinical features, which range from functioning tumors that might present with 
clinical/hormonal syndromes, to non-functioning tumors in terms of their capacity of 
synthetizing and secreting hormones and enzymes (Modlin et al., 2008; Modlin et al., 2010; 
Rindi & Wiedenmann, 2011). GEP-NETs also include a broad gamut of tumors, from very 
indolent to highly aggressive carcinomas (Uccella, Sessa, & Rosa, 2015). These solid 
tumors are characterized by a common neuroectodermal embryological origin and different 
clinical evolution displaying a broad spectrum of characteristics concerning behavior during 
growth and differentiation, functional aspects, localization and prognosis (Briest & 
Grabowski, 2014; Pusceddu et al., 2015). GEP-NETs represent 70% of all NETs and 2% of 
all digestive tract tumors (Modlin et al., 2008; Öberg, 2009; Singh & Law, 2012). Although 
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previously considered rare among neoplastic diseases in general, recent epidemiological 
studies have revealed that the incidence (3.6/100.000) and prevalence (35/100.000) of 
GEP-NETs has increased exponentially throughout the last decade, which has been 
attributed to the increased awareness, as well as, improved sensitivity of the imaging and 
endoscopic techniques employed. Currently, GEP-NETs are the second most common 
gastrointestinal malignancy after colorectal cancer (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Fraenkel, Kim, Faggiano, de Herder, & Valk, 
2013; Meeker & Heaphy, 2014). 
Since their first description in 1907 as carcinoid tumors or carcinoids, by the German 
physician and pathologist Siegfried Oberdorfer, these morphologically heterogeneous 
tumors have been a matter of debate in terms of their nomenclature and classification 
(Fraenkel, Faggiano, & Valk, 2015; Fraenkel, Kim, Faggiano, de Herder, & Valk, 2013; 
Meeker & Heaphy, 2014). In 1963, Williams and Sandler classified the GEP-NETs into three 
subcategories, based on embryological origin, as foregut (stomach, duodenum, upper 
jejunum and pancreas) tumors, midgut (lower jejunum, ileum, appendix and caecum) 
tumors and hindgut (colon and rectum) tumors (Meeker & Heaphy, 2014; Xiaojiang Yi, 
2013). Later in 2000, the World Health Organization (WHO) defined a new classification 
introducing the terms neuroendocrine tumor (benign carcinoid) and neuroendocrine 
carcinoma (malignant carcinoid). However the term carcinoid, meaning cancer-like, despite 
being incorrect it is still traditionally used for some NE tumors (Klöppel, Perren, & Heitz, 
2004; Meeker & Heaphy, 2014). Since 2010, the WHO/European Neuroendocrine Tumor 
Society (ENETS) new guidelines provided a useful and effective scheme to classify the 
GEP-NETs, based on the degree of histomorphological criteria and on proliferation rate 
(Blank, Schmitt, & Perren, 2015; Meeker & Heaphy, 2014; Xiaojiang Yi, 2013). According 
to this last classification, these tumors are classified in two different prognostic, diagnostic 
and biological broad categories: well-differentiated neuroendocrine tumors (WD-NETs) and 
poorly differentiated neuroendocrine carcinomas (PD-NEC) (Blank, Schmitt, & Perren, 
2015; Pusceddu et al., 2015; Uccella, Sessa, & Rosa, 2015). A third category is represented 
by mixed endocrine-exocrine tumors, with both components, which are classified as mixed 
adenoneuroendocrine carcinomas (MANECs) (Blank, Schmitt, & Perren, 2015; Uccella, 
Sessa, & Rosa, 2015). This classification of GEP-NETs further separates WD-NETs into 
low-grade (G1) and intermediate grade (G2) categories, and PD-NECs into a high grade 
(G3) category (table 1). The tumor grade and classification is dependent on the proliferative 
behavior marked by the mitotic count and the Ki-67 proliferation index; G1, G2, and G3 
tumors are defined as having a Ki-67 index of ≤2%, 3-20%, and >20%, respectively (table1) 
(Blank, Schmitt, & Perren, 2015; Briest & Grabowski, 2014; Pusceddu et al., 2015). 
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Table1- Classification and grading system of gastroenteropancreatic neuroendocrine 
tumors according to WHO/ENETS 2010 guidelines.  
GEP-NETS nomenclature Grading Mitotic 
Count 
(10HPF)* 
Ki-67 
index (%) 
WD-NETs Grade 1 (G1) <2 ≤2 
WD-NETs Grade 2 (G2) 2-20 3-20 
PD-NECs Grade 3 (G3) >20 >20 
*10 HPF (high power fields): 2mm2 at least 40 fields      
 
Despite the progress in understanding GEP-NETs, diagnosis is often challenging and 
complicated due to the high heterogeneity of the biological and clinical features: lack of 
symptoms in the early stages, high frequency of non-specific gastrointestinal symptoms and 
the absence of tumor markers (Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, 
& Kapitanovic, 2014; Singh & Law, 2012; Uccella, Sessa, & Rosa, 2015). The delay in 
diagnosis often leads to patients presenting with advanced disease, often exhibiting 
metastases, and thus with a poor prognosis. Consequently, there is still a medical need for 
a better and earlier diagnosis, which is crucial for the starting point of the optimal treatment 
(Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Singh & 
Law, 2012; Uccella, Sessa, & Rosa, 2015). For advanced disease, surgery, biotherapy, 
targeted therapies and chemotherapy are the best available thought limited therapeutic 
approaches to prolong survival but still not satisfactory, possibly due to the crosstalk in 
reactivate mitogen signaling. The only reliable curative treatment is early detection and 
surgical removal (Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 
2014; Giandomenico, Thirlwell, & Essand, 2015; Modlin et al., 2008; Rindi & Wiedenmann, 
2011).  
Chromogranin A (CgA), is expressed in 80-90% of patients with GEP-NETs together with 
synaptophysin, is the most useful and reliable serum tumor marker for the assessment of 
GEP-NETs however with some limitations (Blank, Schmitt, & Perren, 2015; Cigrovski 
Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Singh & Law, 
2012).The major problem that clinicians and scientists face in overcoming GEP-NETs is 
related to various phenomena within tumor biology and molecular pathogenesis. How 
signaling networks contribute to tumor progression and how these networks interact 
remains largely unclear, due to a lack of broad mechanistic knowledge and lack of research 
for novel predictive biomarkers. Therefore, there is an unmet need to identify unique 
biomarkers to improve the knowledge of GEP-NETs pathogenesis, to assess follow-up in 
terms of treatment efficacy, relapse and prognosis, as well for developing and identifying 
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the best therapeutic options (Briest & Grabowski, 2014; Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Giandomenico, Thirlwell, & Essand, 2015). 
 
1.3- Metabolic Syndrome 
Metabolic syndrome (MS) is a cluster of interconnected clinical and biochemical factors that 
predict the increased risk of atherosclerotic cardiovascular disease, type 2 diabetes (T2D) 
and mortality. These risk factors incorporate central obesity, high blood pressure (BP), 
raised triglycerides, low high-density lipoprotein (HDL) and high fasting plasma glucose 
(Alberti et al., 2009; Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012; Giugliano, Ceriello, 
& Esposito, 2006; Kaur, 2014). MS initial concept was described in 1920 by a Swedish 
physician named Kylin when the association between high BP, high fasting plasma glucose 
and gout was described. Later in 1988, Reaven was responsible for the revival and progress 
of MS when he postulated a “cluster of risk factors for diabetes and cardiovascular diseases” 
that was designated by “Syndrome X” (Hanefeld, Pistrosch, Bornstein, & Birkenfeld, 2016; 
Kaur, 2014). Since then, a wide variety of MS clinical definitions have appeared throughout 
times with common and diverse risk factors which led to some confusion and discussion. 
Nowadays, MS is a common medical term with a concrete diagnosis, but is not well 
recognized as a clinical entity. The most recent criteria used to diagnose MS are from a 
jointly effort of several institutions (Alberti et al., 2009; Kaur, 2014). According to this joint 
scientific statement, MS is defined by the presence of at least three out of the five risk 
factors: diabetes or high fasting plasma glucose, central obesity/visceral obesity, raised 
triglycerides, low HDL and high BP (Alberti et al., 2009). The criteria and respective 
reference values are showed in table 2. It is estimated that people with MS are twice as 
likely to die, three times as likely to have a myocardial infarction or stroke and a five-fold 
greater risk of developing T2D, when compared with people without the syndrome (Alberti 
et al., 2009; Kaur, 2014). 
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Table 2- Criteria for MS clinical diagnose and definition (adapted from Alberti et al., 2009). 
Criteria Reference Values Additional 
information 
 
 
Central obesity (defined as waist circumference*) 
*with ethnicity specific values 
≥ 94 cm (increased 
risk) and ≥ 102 cm 
(still higher risk) in 
 European males 
Or 
≥ 80 cm (increased 
risk) and ≥ 88 cm 
(still higher risk)  in 
European females 
 
if BMI is >30kg/m², 
central obesity can 
be assumed. 
 
Raised triglycerides 
 
≥ 150 mg/dL  
 
or specific 
treatment for this 
anomaly 
 
 
 
Low HDL 
< 40 mg/dL  
in males 
or 
< 50 mg/dL  
in females 
 
or specific 
treatment for this 
anomaly 
 
 
High blood pressure 
Systolic BP ≥ 130 
mm Hg 
or 
Diastolic BP ≥ 85 
mm Hg 
 
or specific 
treatment for this 
anomaly 
 
High fasting plasma glucose 
 
≥ 100 mg/dL 
or previously 
diagnose T2D 
 
In parallel with the increasing rate of GEP-NETs, obesity, MS and diabetes are also major 
and escalating public-health and clinical problems worldwide (Kaur, 2014; Vigneri, Frasca, 
Sciacca, Pandini, & Vigneri, 2009; Zeyda & Stulnig, 2009). The International Diabetes 
Federation estimates that a quarter of the world’s adult population has the MS and that it is 
starting to be a serious ubiquitous health concern throughout the world. It is reported that 
worldwide prevalence of MS ranges from <10% to as much as 84%, depending on the 
region, urban or rural environment, composition (sex, age, race, and ethnicity) of the 
population studied (Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012; Kaur, 2014). In 
United States, MS is highly prevalent and affects more than 35% of the population, which 
is translated in nearly 80 million adults affected (Esposito, Chiodini, Colao, Lenzi, & 
Giugliano, 2012; Giugliano, Ceriello, & Esposito, 2006). MS is also consistently associated 
with an increased risk and mortality of several cancers in adults and for some cancers the 
risk differs between sexes and populations (Esposito, Chiodini, Colao, Lenzi, & Giugliano, 
2012). Some studies also revealed the correlation between MS individual components and 
cancer risk. Obesity and diabetes, contributing factors for MS prevalence and risk, have 
frequently been correlated with a raised risk for several types of cancers, such as gastric 
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adenocarcinoma, pancreatic, colorectal, liver, breast and esophageal cancer among others 
(Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012; Lin, Ness-Jensen, Hveem, Lagergren, 
& Lu, 2015; Vigneri, Frasca, Sciacca, Pandini, & Vigneri, 2009). Despite the available facts, 
the precise etiology and molecular mechanisms that connect MS to the development, 
progression and cancer mortality are not entirely understood (Esposito, Chiodini, Colao, 
Lenzi, & Giugliano, 2012). The link between MS, its components and cancer has been 
recently demonstrated for several types of neoplasia, however the association with NETs 
has not so far been reported, although it deserves to be explored. 
Obesity, diabetes, and MS are closely related with a low grade inflammatory state 
(Giugliano, Ceriello, & Esposito, 2006; Vigneri, Frasca, Sciacca, Pandini, & Vigneri, 2009; 
Zeyda & Stulnig, 2009). MS is a state of chronic low grade inflammation due to the 
contribution of the interaction among components of the clinical syndrome phenotype with 
its biological phenotype, resulting in deep systemic effects (Hanefeld, Pistrosch, Bornstein, 
& Birkenfeld, 2016; Kaur, 2014). Since a long time an association between chronic 
inflammation, visceral obesity and insulin resistance has been known. This association is 
characterized by abnormal production of inflammatory cytokines, such as, tumor necrosis 
factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), leptin, 
osteopontin and adiponectin by both adipocytes and infiltrate immune cells, resulting in a 
pro-tumorigenic environment and elevated plasma levels (Esposito, Chiodini, Colao, Lenzi, 
& Giugliano, 2012; Kaur, 2014; Zeyda & Stulnig, 2009). Recent studies indicate that chronic 
low-grade inflammation plays a key role in metabolic deterioration in the obese population, 
where adipose tissue is as the key source for increased pro-inflammatory cytokines during 
obesity and circulating monocyte/macrophages in adipose tissue contribute to both the pro-
inflammatory state and insulin resistance of MS. So these studies suggest that obesity 
associated systemic chronic low grade inflammation is a major risk factor for the 
development of MS and associated health complications (Esposito, Chiodini, Colao, Lenzi, 
& Giugliano, 2012; Sun, Ji, Kersten, & Qi, 2012; Zeyda & Stulnig, 2009). As a result of a 
complex interplay between genetic and environmental factors MS is a state of chronic low 
grade inflammation. However, the mechanisms of origin pathophysiology and mode of 
perpetuation of such inflammation are not quite completely known (Kaur, 2014). 
 
1.4- Inflammation and cancer 
A causal relationship between inflammation and cancer has been suspected for a long time, 
due to the contribution of Galen (Greten & Karin, 2004). Since the early pathology studies 
in the 1800s, Rudolf Virchow demonstrated the presence of leucocytes in malignant tissues 
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claiming that tumors arise from regions of chronic inflammation, thus providing the first 
evidence between inflammation and cancer (Balkwill & Mantovani, 2001; Greten & Karin, 
2004; Grivennikov, Greten, & Karin, 2010). However, it was only during last decades that 
became evident that inflammation affects immune surveillance, response to therapy and 
plays a vital role in tumorigenesis. Therefore, the importance of the inflammatory response 
in tumor initiation and malignant progression has assumed prominence enabling that the 
mechanisms that link infection, innate immunity, inflammation, and cancer be revealed at a 
fast pace (Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; 
Grivennikov, Greten, & Karin, 2010; Lin & Karin, 2007; Yu, Pardoll, & Jove, 2009). 
Inflammatory response is in many aspects similar with a regenerative or scaring response, 
although subverted, and in the past tumors have been considered as wound that do not 
heal (Balkwill & Mantovani, 2001; Grivennikov, Greten, & Karin, 2010). Despite this 
increasing knowledge, the exact molecular nature of the link between inflammation and 
cancer remains somewhat vague and needs to be further characterized (Greten & Karin, 
2004). 
It has become clear that diverse types of inflammation can promote or inhibit the induction 
and growth of cancer. As seen in inflammatory bowel disease (IBD) and chronic pancreatitis 
an elevated risk is respectively associated with colorectal cancer or pancreatic 
adenocarcinoma, demonstrating that the carcinogenesis in the gastrointestinal tract and 
pancreas is often associated with chronic inflammation (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Grivennikov, Greten, & Karin, 2010). As a 
matter of fact, several human cancers arise and progress under conditions of a chronic 
inflammatory state, once chronic inflammation orchestrates a microenvironment that is an 
indispensable part in the neoplastic process (Grivennikov, Greten, & Karin, 2010; Lin & 
Karin, 2007). Although chronic inflammation increases cancer risk, the exact molecular 
mechanism by which promotes tumor is not yet entirely known and therefore understood 
(Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014). 
The aforementioned inflammatory response can stimulate tumorigenesis at different stages, 
initiation, promotion, malignant transformation, invasion and metastasizing, while 
inflammation, mainly acute inflammation, together with immunity is able to inhibit tumor 
growth and even also to eliminate some tumors (Cigrovski Berkovic, Cacev, Catela Ivkovic, 
Zjacic-Rotkvic, & Kapitanovic, 2014; Grivennikov, Greten, & Karin, 2010; Lin & Karin, 2007). 
Nowadays has become evident that an inflammatory microenvironment is an essential 
component of all tumors, even though in some tumors a direct causal link is not yet proved. 
In the tumor microenvironment, there is a delicate balance between anti-tumor immunity 
and pro-inflammatory activity (Grivennikov, Greten, & Karin, 2010; Lin & Karin, 2007). The 
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direction in which the balance is tipped depends of growth factors, matrix degrading 
enzymes, reactive oxygen species (ROS) and the expression of different existing mediators, 
like cytokines, chemokines among others, in tumor microenvironment, which are released 
by host immune and inflammatory cells, cancer cells, and other types of host tumor 
associated cells, like fibroblasts and endothelial cells (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Coussens & Werb, 2002; Lin & Karin, 2007). 
Immune cells that infiltrate the tumor and other surrounding cells are involved in an 
extensive and dynamic crosstalk with tumor cells (Grivennikov, Greten, & Karin, 2010). 
Genetic and epigenetic alterations in malignant cells also can generate an inflammatory 
microenvironment supporting tumor progression. So, during tumorigenesis the host-
mediated anti-tumor immunity is suppressed and at the same time pro-inflammatory activity 
is favored and thus leading to tumor development (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014). 
Regarding the different mediators present in tumor microenvironment it is most important 
to highlight that cytokines are the main mediators responsible for shaping the 
microenvironment. The cytokines profile predominantly expressed in tumor 
microenvironment is able either to favor pro-inflammatory activity, promoting tumor growth, 
or anti-tumor activity, suppressing tumor growth, by controlling the direction in which the 
delicate balance is tilted (Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & 
Kapitanovic, 2014; Lin & Karin, 2007). Usually, independently of their source cytokines are 
divided in two main groups: pro-inflammatory group, IL-1, IL-6, IL-8, interleukin-11, 
interleukin-12 (IL-12), interleukin-18, interleukin-23 (IL-23), TNF-α, among others, which 
can contribute to tumor development and progression and the anti-inflammatory group, 
interleukin-4, interleukin-10 (IL-10), interferon-alpha, interferon-beta, transforming growth 
factor-beta (TGF-β), among others, which can contribute to the inhibition of tumor 
development and progression (Cigrovski Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & 
Kapitanovic, 2014; Grivennikov, Greten, & Karin, 2010). In both of these groups, certain 
cytokines, like TNF-α, interleukin-1 alpha, interleukin-1 beta (IL-1β), IL-6, IL-10, IL-12, 
interleukin-17 (IL-17), TGF-β and IL-23, are associated with fostering a particular direction, 
although some cytokines can have a bifold performance (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Lin & Karin, 2007). Indeed, some studies have 
been consistently revealing and associating a crucial role of TNF-α, IL-6, IL-1β and IL-17 in 
tipping the balance into pro-inflammatory activity and thus in the initiation of chronic 
inflammation, resulting in a support to tumor growth and progression via the stimulation of 
different pathways and several downstream effectors (Coussens & Werb, 2002; 
Grivennikov, Greten, & Karin, 2010; Lin & Karin, 2007). The activation with different 
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mediators of nuclear factor-kappa B (NF-kB) and signal transducers and activator of 
transcription 3 (STAT3) pathways are crucial for the initiation, progression, tumor-promoting 
inflammation and survival of several cancers. The persistence activation of NF-kB and 
STAT3 signaling pathways in multiple cancers is due to a process of an autocrine or 
paracrine loop. These feed-forward loops are established through a tumor associated 
inflammation that upregulate mediators capable to attract immune and inflammatory cells 
that further propagate the pathways activity by the production of different mediators, mainly 
IL-6 and IL-1β, or due to the control and induction of the transcription of genes that encode 
pro-inflammatory cytokines, such as TNF-α and IL-6 (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Greten et al., 2004;Yu, Pardoll, & Jove, 2009). 
Recent reports have revealed that there is a considerable higher incidence of a chronic 
inflammatory environment in GEP-NETs. For instance, research have shown an increased 
risk for developing of gastrointestinal neuroendocrine tumors in IBD. It has been 
hypothesized that chronic inflammatory conditions stimulate enteroendocrine cells and 
consequently leading to hyperplasia and possibly to neoplastic transformation (Cigrovski 
Berkovic, Cacev, Catela Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014; Le Marc'Hadour et 
al., 1994). Studies pinpoint a role for cytokines in NETs, suggesting that IL-1 and interleukin-
2 could have role in alterations, differentiation and regulation of a neuroendocrine system 
and in the interaction with immune system (Qian, El-Salhy, Melgar, Hammarstrom, & 
Danielsson, 2000; Sun, 2004). GEP-NETs express a variety of mediators including a 
diverse group of growth factors, cytokines, enzymes and tyrosine kinase receptors that are 
used as targets for the development of new therapies (Cigrovski Berkovic, Cacev, Catela 
Ivkovic, Zjacic-Rotkvic, & Kapitanovic, 2014). Nowadays, the influential role of inflammation 
in tumorigenesis is widely accepted, and it has become evident that an inflammatory 
microenvironment is an essential component of all tumors (Grivennikov, Greten, & Karin, 
2010). Despite that, this role and association of inflammation and tumor microenvironment 
in GEP-NETs is still not completely understood. 
 
1.5- Cellular signaling and NETs 
The understanding of GEP-NETs signaling pathways, in terms of their molecular 
mechanisms and interactions, is still far from a sharp molecular awareness (Briest & 
Grabowski, 2014). It is known that cell signaling in NETs influence nearly all aspect of 
cancer pathophysiology, such as malignant transformation, progression and metastasis, 
through the activation of several signaling pathways. Generally, NETs signaling activation 
involves the activation of several receptors, such as tyrosine kinase receptors (TKRs) and 
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G-protein coupled receptors, leading to the activation of downstream cell signaling 
cascades and resulting in an increased DNA synthesis, angiogenesis, cell proliferation, 
survival,  migration, growth and secretion (Figure 1). Receptor activation is due to the linking 
of their ligands, mainly growth factors. GEP-NETs express a wide variety of growth factors, 
vascular endothelial growth factor (VEGF), platelet-derived growth factor, insulin-like growth 
factor 1 (IGF-1), transforming growth factor, somatostatin among many others and in vitro 
studies, suggest that tumor growth depends on the activation of some growth factor 
receptors. Of the several signaling networks those considered to be the most important in 
neuroendocrine biology are phosphatidylinositol 3-kinase (PI3k)/AKT/mammalian target of 
rapamycin (mTOR), RAS/RAF/ mitogen-activated protein kinase (MAPK), phospholipase 
C-protein kinase C (PLC/PKC), and Janus kinase–signal transducer and activator of 
transcription (JAK/STAT) (Figure 1) (Briest & Grabowski, 2014; Giandomenico, Thirlwell, & 
Essand, 2015; Raymond et al., 2011). 
 
 
 
Figure 1- Neuroendocrine cell signalization and involved pathways (adapted from Raymond 
et al., 2011). 
The major pathways involved in neuroendocrine tumor biology are MAPK and PI3K-Akt-
mTOR. The MAPK signaling pathway has been identified and amply studied for more than 
three decades, but researchers are still puzzled by the intricate dynamic control and 
plasticity of its kinases (Fey, Matallanas, Rauch, Rukhlenko, & Kholodenko, 2016; Rauch, 
Rukhlenko, Kolch, & Kholodenko, 2016). This cascade is a pivotal signaling pathway that 
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comprises several ubiquitously expressed kinases, from membrane to nucleus, that 
regulate a wide variety of cellular functions, including cell proliferation, growth, 
differentiation, survival/apoptosis, migration, transformation, metabolism, transcription and 
translation, in response to a plethora of internal/external signals, such as growth factors, 
cytokines, chemokines, extracellular matrix, ROS, drugs among many others (Briest & 
Grabowski, 2014; Cuevas, Abell, & Johnson, 2007; Rauch, Rukhlenko, Kolch, & 
Kholodenko, 2016). Enduring temporal alterations of the MAPK cascade has been 
frequently associated with a key role in multiple diseases. In truth, MAPK cascade is one of 
the most frequently affected pathways and their deregulation is associated with several 
cancers, development disorders and other human diseases, including inflammatory and 
proliferative diseases (Cuevas, Abell, & Johnson, 2007; Fey, Matallanas, Rauch, 
Rukhlenko, & Kholodenko, 2016; Rauch, Rukhlenko, Kolch, & Kholodenko, 2016). 
The MAPK pathway is constituted by different cascades, being the classic cascade one of 
the most important pathways (ERK/MAPK pathway). This classic cascade is induced by 
ligand binding to TKRs, such as vascular endothelial growth factor receptor, epidermal 
growth factor receptor or insulin-like growth factor receptor, leading to the sequential 
phosphorylation of specific substrate proteins of a dynamic protein kinase network which 
are frequently mutated in cancer and are drug targets (Briest & Grabowski, 2014; Rauch, 
Rukhlenko, Kolch, & Kholodenko, 2016). MAPK pathways are associated with STAT3 
phosphorylation leading to the stimulation of cytokine production, induction of pro-
angiogenic factors and invasion in tumor cells (Briest & Grabowski, 2014). Multiple 
crosstalks and feedback loops, both positive and negative, between pathways brings a 
complex dynamic inducing resistance to therapy and bypass inhibitory approaches (Fey, 
Matallanas, Rauch, Rukhlenko, & Kholodenko, 2016; Rauch, Rukhlenko, Kolch, & 
Kholodenko, 2016). In NETs, the MAPK pathway is highly activated, although the activation 
mechanisms is not clear, contributes to neuroendocrine tumorigenesis and is highly 
involved in the triggering of a neuroendocrine phenotype (Briest & Grabowski, 2014). 
The unique ubiquitous PI3K signaling pathway is frequently activated in several human 
cancers by different mechanisms and is one of the fundamental pathways involved in 
cancer development and preservation (Wong, Engelman, & Cantley, 2010; Yuan & Cantley, 
2008). PI3K activation is carefully regulated by the interactions between ligands, such as 
growth factors, and TKRs that directly or indirectly activate the downstream signaling 
cascade (Wong, Engelman, & Cantley, 2010; Yuan & Cantley, 2008). TKRs integrate and 
propagate the signal from the extracellular growth factors, like VEGF, IGF-1, fibroblast 
growth factor, to effector proteins of the intracellular signaling cascade that play a critical 
role in controlling a wide range of processes, such as cellular growth, proliferation, motility, 
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survival, insulin signaling, signaling with endothelial and immune cells, inflammation, redox 
status, regulation of membrane trafficking among many other functions (Briest & Grabowski, 
2014; Yuan & Cantley, 2008). The PI3K signaling pathway is generally highly activated and 
deregulated in GEP-NETs, due to vastly expression levels of diverse growth factors and the 
contribution of several feedback loops (Briest & Grabowski, 2014). 
The most promising therapies in GEP-NETs are molecular targeted approaches, targeting 
mTOR protein and somatostatin receptors (Briest & Grabowski, 2014). In insulin resistance 
states, the high insulin levels are known to stimulate MAPK and PI3K-Akt-mTOR pathways, 
which are attenuated by metformin. Metformin lowers circulating insulin levels and indirectly 
stimulates AMP-activated protein kinase activity leading to a reduction of insulin/IGF1 
signaling, and thus suppressing MAPK and mTOR signaling. In addition, metformin has 
also demonstrated anti-cancer properties, through the inhibition of cell growth and signaling, 
on neuroendocrine cells in vitro (Vigneri, Frasca, Sciacca, Pandini, & Vigneri, 2009; Vlotides 
et al., 2014).  
Recent evidence allowed to disclosure the complicated and multifactorial role of the insulin-
like growth factor one receptor (IGF1R) pathway in the development and progression of 
several tumors. More specifically, increased expression of IGF1 and IGF1R has been 
involved in the progression of different types of tumors, including breast, lung and endocrine 
tumors among others (Raymond et al., 2011; Samani, Yakar, LeRoith, & Brodt, 2007).  
IGF1R is one of the crucial TKRs in GEP-NETs biology, where the activation and 
participation of all components of the IGF are necessary for the occurrence of the 
tumorigenic process (Briest & Grabowski, 2014; Raymond et al., 2011). In physiological 
conditions, IGF1R expression is under a tightly balanced control and any disturbance can 
induce the activation of a downstream molecular cascade. The increase expression of both 
IGF1R and IGF1 by different tumors, including gastrinomas, were associated with tumor 
growth, aggressiveness, decreased survival and poor prognosis (Furukawa et al., 2005; 
Raymond et al., 2011; Samani, Yakar, LeRoith, & Brodt, 2007). Neuroendocrine cells that 
secrete a large amount of IGF-1, lead to IGF1R activation and consequently to a high 
expression of these TKRs and its ligand (Briest & Grabowski, 2014). IGF-1 and insulin are 
weak activators of MAPK pathway but strong activators of the PI3K-Akt-mTOR pathway 
(Raymond et al., 2011). It was also demonstrated that IGF1 can be a major autocrine 
regulator of neuroendocrine tumor growth and secretion through the activation of complex 
molecular networks (Briest & Grabowski, 2014). IGF receptors are potential molecular 
targets for a variety of therapies in GEP-NETs and several inhibitors and monoclonal 
antibodies for IGFR1 are currently under trial (Briest & Grabowski, 2014; Raymond et al., 
2011). 
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The Forkhead box M1 (FOXM1) is a common proliferation-associated transcription factor, 
which is a member of the forkhead box (FOX) transcription superfamily that regulates 
several biologic processes (Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 2013). FOXM1 is 
an essential transcription factor in neoplastic cells of a variety of human solid cancers, 
including GEP-NETs, and is usually associated with cell cycle progression, cell 
development, differentiation, proliferation, apoptosis, tissue homeostasis and angiogenesis 
(Briest et al., 2015; Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 2013). This transcription 
factor is one of the first’s up-regulated proteins in tumorigenesis, with an important function 
in tissue repair, DNA replication and mitosis, and their role in all of the hallmarks of cancer 
has been proposed and demonstrated (Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 2013; 
Wierstra, 2013). More specifically, FOXM1 regulates the expression of cell cycle genes, 
whose products control the transitional progress of the G1/S-phase G2/M-phase cell cycle 
checkpoints and are associated with the regulation of mitotic spindle integrity for a proper 
mitosis (Halasi & Gartel, 2013; Halasi & Gartel, 2013; Wierstra, 2013). FOXM1 transcription 
factor belongs to the PI3K-Akt-Forkhead Box O (FOXO) pathway, where it is an important 
downstream effector of this cascade that can be repressed by wild type p53 or Forkhead 
O3a (FOXO3a) (Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 2013; Wierstra, 2013). 
FOXM1 is a transcriptional target of STAT3 and in GEP-NETs they are unitedly upregulated. 
This pathway is also commonly deregulated in gastrointestinal NETs (Briest et al., 2015; 
Wierstra, 2013). MAPK and PI3K pathways, the most frequently deregulated pathways in 
cancer, establish a crosstalk with FOXM1 pathway (Halasi & Gartel, 2013; Wierstra, 2013). 
In a study, FOXM1 expression was strongly correlated with tumor differentiation, 
proliferation and metastasis suggesting that could possibly be used as a prognostic factor 
and as a therapeutic target for gastrointestinal NETs (Briest et al., 2015). A study 
demonstrated a correlation between FOXM1 and Ki-67 and that FOXM1 were 
predominantly expressed in high grade neuroendocrine tumors, G2 and G3 tumors, than in 
carcinoid tumors (Briest et al., 2015). The expression of some proteins, like IGF-1, is altered 
in GEP-NETs and a study in cardiomyocytes showed that a downregulated FOXM1 
expression is associated with a downregulated IGF1R expression (Briest & Grabowski, 
2014; Sengupta, Kalinichenko, & Yutzey, 2012). The overexpression of this crucial factor 
promotes resistance to chemotherapy and other genotoxic drugs of several human cancers 
leading to cancer cell growth and survival (Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 
2013; Halasi & Gartel, 2013). Furthermore, studies with siomycin A, an inhibitor of FOXM1, 
in GEP-NETs and metastatic melanoma cell lines in vitro induced a decreased in the mitotic 
activity, due to a down-regulation of mitotic proteins that results in mitotic catastrophe, 
inducing apoptosis and presenting synergic effects with conventional chemotherapy (Bhat, 
Zipfel, Tyler, & Gartel, 2008; Briest et al., 2015). Although the increasing knowledge, there 
27 
 
is still a need for a better understanding of FOXM1 role and mechanistic action in NETs and 
further studies need to be done. 
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Chapter 2- Objective 
The main objective of this project was to evaluate the influence of metabolic syndrome 
criteria and their individual parameters in the expression of different molecular markers that 
participate in metabolic and inflammatory pathways in neuroendocrine tumors and peri-
tumoral tissue, as well as, their correlation with the tumor clinical and pathologic features.  
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Chapter 3- Materials and Methods  
3.1- Human tumor samples 
Paraffin-embedded neuroendocrine tumor tissue (n= 39) collected from patients under 
routine follow up at the Endocrine Tumors Clinic of the Portuguese Institute of Oncology in 
Porto were selected and used. These selection only included patients with NETs from the 
gastroenteropancreatic system with the demographics and tumor pathological features 
presented in table 3 and table 4. In table 3, the divergence between number of patients and 
sum of studied parameters translates missing data.   
Table 3- Characterization of patients and tumors characteristics.  
Parameters Pancreas (n=10) Gastrointestinal (n=29) 
Median Age, years 
(range) 
57 (29-75) 64 (41-81) 
Sex F:M 6:4 12:17 
WHO grade G1:G2 6:4 24:5 
 
T T1:T2:T3:T4 
 
3:3:1:2 
 
 
4:6:9:7 
N N0:N1 8:1 5:19 
M  
M0:M1 
7:3 9:20 
Functioning  
Yes:No 
2:7 22:7 
GI-NETs location   Duodenum (n=4), Ampoule (n=1) 
Jejunum (n=1), Ileum (n=20), 
Appendix (n=3)  
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Table 4- Characterization of patients characteristics in terms of MS and its parameters.  
Parameters Pancreas (n=10) Gastrointestinal (n=29) 
MS 
 Present:Absent 
6:4 20:9 
Tumor grade  
MS Present:Absent 
G1- 4:2 
G2- 2:2 
G1- 17:7 
G2- 3:2 
Waist 
circumference 
Normal:Raised 
3:6 12:17 
BP  
Normal:Raised 
4:6 9:20 
Triglycerides 
Normal:Raised 
4:6 16:13 
HDL 
Normal:Decreased 
5:5 13:16 
High fasting plasma 
glucose 
Normal:Raised 
4:6 9:20 
 
 
3.2- Immunohistochemistry 
In order to evaluate the inflammatory state of the tumors adjacent tissue and understand 
the influence of MAPK and mTOR pathways in the biology of neuroendocrine tumors 
immunohistochemical analysis were performed. Therefore individual analysis for the 
presence of IL-6, FOXM1 and IGF1R proteins were respectively accomplished.  
For this immunohistochemistry study the positive and negative internal controls used were 
breast cancer (IGF1R), colon (FOXM1) and tonsil tissue (IL-6).     
The tissue sections of 3 µm were dewaxed in xylene and progressively rehydrated in a 
decreasing scale of alcohols (100%, 95% and 70%) up until to water. Antigenic retrieval 
was done differently according to the different types of markers molecules. For IL-6  antigen 
retrieval was made by incubation in a 10 mM citrate buffer (pH 6,0) with Tween 20 at 0,05%, 
in a microwave at 900 W during 20 minutes after boiling. For FOXM1 antigen retrieval was 
made by incubation in a 10 mM citrate buffer (pH 6,0) with Tween 20 at 0,05%, in a 
microwave at 900 W during 25 minutes after boiling. For IGF1R protein, antigen retrieval 
was made by incubation in a 10 mM citrate buffer (pH 6,0) with Tween 20 at 0,05%, in a 
pressure cooker during 4 minutes after  boiling. All of the washes required throughout the 
process were performed with a phosphate buffered saline solution with Tween 20 at 0,05% 
(pH 7,4). Endogenous peroxidase was inhibited with the incubation of the sections in a 
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solution of hydrogen peroxide and methanol at 3% during 20 minutes. Slides were then 
mounted in the Sequenza Immunostaining Center (Thermo Scientific Shandon) and the 
sections were incubated with a serum solution (dilution 1:5 in BSA 10%) to ensure the 
blocking of unspecific marking, during 30 minutes. For the different proteins different serums 
were used: rabbit serum for IL-6 and swine serum for FOXM1 and IGF1-R. 
Incubation with the respective primary antibody, was performed overnight at 4ºC in the 
conditions described in the table 5. The negative control was incubated only with 5% BSA. 
Table 5- Characteristics and dilutions of primary antibodies.  
Primary Antibody Anti-IGF1R Anti-FOXM1 Anti-IL-6 
Brand and 
reference 
Abcam 
 
Ref: ab39675 
Santa Cruz 
Biotechnology 
Ref: (C-20): sc-502 
Abcam 
 
Ref: ab9324 
Dilution in 5% BSA 1:100 1:500 1:500 
 
Subsequently the sections were incubated with the proper secondary antibody (Table 6) 
during 30 minutes at room temperature. 
Table 6- Characteristics and dilutions of secondary antibodies. 
 
Secondary Antibody 
Polyclonal 
Rabbit anti-Mouse 
Biotinylated 
Polyclonal  
Swine anti-Rabbit 
Biotinylated 
Brand and  
Reference 
Dako Cytomation  
E0354 
Dako Cytomation 
E0353 
Dilution in 5% BSA 1:200 1:200 
Used against  IL-6 FOXM1 and IGF1R 
 
After that, sections were incubated during 30 minutes with an avidin-biotin complex (Vector 
A and B, in a 1:100 dilution in BSA 5%) and then revealed with the DAB substrate (3,3’-
Diaminobenzidine tetrahydrochloride, Dako) during different times for the different 
antibodies (IL-6 (30 seconds), FOXM (1minute), IGF1R (2 minutes)). The revelation process 
was stopped with running water, 10 minutes, after which the sections were counterstained 
with Harris Hematoxylin, three dives, followed by a 10 minute wash in running water. Finally, 
the blades with the sections were progressively dehydrated in an increasing scale of 
alcohols (70%, 95% and 100%), cleared with xylene and mounted with Entellan. 
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Tissue slides immunohistochemically stained for the Ki-67 marker routinely performed to 
determine the tumor grade were retrieved from the IPO-PORTO pathology department 
archives and used for morphological analysis. 
 
3.3- Immunohistochemical data analysis  
Hematoxylin-Eosin stained slides were used for tumor area delimitation based in 
morphologic criteria by the same experienced pathologist with no access to patients’ clinical 
information. This area delimitation was then transferred to the immunohistochemistry 
stained slides. 
After the immunohistochemistry, slides were scanned using the image acquisition Olympus 
VS110 virtual slide scanning system and captured with a magnification of 20x using the 
image acquisition software VS-ASW. Images were analyzed using the image processing 
software FIJI (Life Line Version from June 2nd 2014 for Macintosh, National Institutes of 
Health – USA).  
The neuroendocrine tumor area was selected using Fiji freehand tool, for the study of the 
expression of Ki-67, FOXM1 and IGF1R. A peri-tumoral area 5mm distant from the tumor 
and from 5mm till the end of the tissue was delimited using a macro for Fiji developed by 
Professor Paula Sampaio (I3S, IBMC) to evaluate IL-6 expression. This macro is based in 
the ROI Manager Tool of FIJI.  
Using FIJI color deconvolution plugin (H Dab), which allows the separation of the stained 
area from the initial image, based in the RGB system (Red, Green and Blue), the stained 
area with the antibodies in the total tissue area of the tumor and adjacent tissue were 
quantified.  
Using just one of the images provided by the color deconvolution (red) the threshold 
command was used to transform the image in a black and white binary system allowing to 
quantify the stained area (brown staining with Dab) for the different analyzed regions. Then 
the Fiji command analyze particles was selected to introduce the results (total stained area). 
Each one of the individual starting images was duplicated and converted in a 16 bits format 
(shades of gray). Using this converted 16 bits image a new threshold command was applied 
in order to allow to quantify the total area for the different analyzed regions. After that the 
option analyze particles was chosen to show the results of interest (total area). Finally, the 
percentage of the stained area for the different analyzed regions (Neuroendocrine tumor- 
Ki-67, IGF1R and FOXM1; tumors adjacent tissue- IL-6) was assessed by calculating the 
ratio between the antibody stained area in these regions and the respective total area.  
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3.4- Correlation of the immunohistochemical results with the patients and tumor 
characteristics  
After the immunohistochemical analysis, the results were correlated with metabolic 
syndrome and its components. More specifically the criteria selected for the correlation with 
immunohistochemistry were presence or absence of MS, normal and abnormal levels of 
waist circumference, HDL, triglycerides, BP, high fasting plasma glucose (MS components). 
 
3.5- Statistical analysis  
Qualitative variables are expressed as number of cases and percentage (%), and the 
quantitative variables are expressed as mean and standard error of the mean. The 
difference between two independent experimental groups was evaluated using the unpaired 
Student t test for normally distributed variables, and the Mann-Whitney U test for variables 
that did not meet the normal parameters. To compare 3 or more independent groups with 
normal distribution we used a simple analysis of variance (one-way ANOVA) with post-hoc 
Newman Keuls test. Kruskal-Wallis ANOVA with Dunns post hoc was used to compare 3 
or more groups when a sample did not meet the criteria of normality. To correlate the 
different groups, a Pearson or Spearman correlation was used as the normality of the 
samples. A p value <0.05 was considered statistically significant. All statistical analyses 
were performed with the aid of the Graphpad Prism software version 7.00 and IBM SPSS 
Statistics version 24, both for Windows. 
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Chapter 4- Results 
The immunohistochemical studies for appraisal of the expression of KI-67, FOXM1, IGF1R 
and IL-6, was performed in all tissue samples and the percentage of the stained area (tumor 
or peri-tumoral area) was calculated and determined using the ImageJ software (Figure 2). 
Figure 2 - Histological photographs of ileal GI-NET and pancreatic NETs sections 
immunohistochemically stained for Ki-67, IGF1R, FOXM1 and IL-6.  
 Pancreatic Gastrointestinal 
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4.1- Expression of Ki-67, FOXM1, IGF1R and IL-6 markers in patients with or 
without metabolic syndrome 
The percentages of the stained tumor areas in the patients with or without SM were not 
significantly different in both pancreatic and gastrointestinal NETs for all of the studied 
molecular markers, Ki-67, FOXM1 and IGF1R (Graph 1). Despite the absolute value of the 
percentage of stained area for IGF1R being higher in patients with MS both in pancreatic 
and gastrointestinal NETs it was not statistically significant (Graph 1).  
 
Graph 1- Percentage of the stained area in GEP-NETs of patients with or without MS for 
the Ki-67, FOXM1 and IGF1R proteins. 
The percentage of the IL-6 stained peri-tumoral area was assessed in two different 
distances from the tumor. The results showed that the IL-6 percentages of the stained areas 
were not statistically significantly different between patients with or without MS in pancreatic 
and gastrointestinal NETs, for both of the peri-tumoral areas at 5mm distance or less from 
the tumor limit and from higher than 5mm till the end of the tissue, (Graph 2). Regardless 
the absolute value of the percentage of stained area for IL-6, at less than 5 mm from the 
tumor limit in pancreatic and gastrointestinal NETs, were higher in patients with MS but not 
statistically significant (Graph 2). 
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Graph 2- Percentage of the stained peri-tumoral area of GEP-NETs of patients with or 
without MS at different distances for the IL-6 protein. 
 
4.2- Expression of Ki-67, FOXM1, IGF1R and IL-6 markers in the patients with or 
without MS parameters   
The percentages of the stained tumor areas for Ki-67, FOXM1 and IGF1R markers, were 
not significantly different between patients with or without each individual MS component 
both for pancreatic and gastrointestinal NETs (Table 7 and Table 8). 
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Table 7- Percentage of the tumor area stained in the immunohistochemical markers, Ki-67, 
FOXM1 and IGF1R, (mean±s.e.m.) in pancreatic NETs. 
MS 
Components 
Ki-67 FOXM1 IGF1R 
 
BP  
normal:raised 
 
 
2.74±1.28:3.73±1.27 
p = 0.61 
 
2.06±0.77:2.68±0.85 
p = 0.62 
 
3.18±1.67:5.51±1.98 
p = 0.47 
Fasting plasma 
glucose   
normal:raised 
 
 
3.78±1.46:3.04±1.20 
p = 0.91 
 
2.67±0.67:2.28±0.89 
p = 0.47 
 
6.18±4.34:4.01±0.87 
p = 0.51 
 
Triglycerides 
normal:raised 
 
 
4.06±1.30:2.85±1.24 
p = 0.48 
 
2.35±0.69:2.49±0.89 
p = 0.76 
 
2.88±1.10:6.22±2.30 
p = 0.27 
 
HDL 
normal:low 
 
 
3.37±1.20:3.29±1.43 
p = 0.84 
 
2.02±0.61:2.85±1.01 
p = 0.5 
 
4.08±1.31:5.26±2.47 
p = 0.71 
 
Central obesity 
absent:present 
 
 
3.02±1.76:2.55±0.73 
p = 0.90 
 
2.21±1.06:1.83±0.26 
p = 0.64 
 
3.90±2.60:4.98±2.08 
p = 0.80 
 
Table 8- Percentage of the tumor area stained in the immunohistochemical markers, Ki-67, 
FOXM1 and IGF1R, (mean±s.e.m.) in GI-NETs. 
MS 
Components 
Ki-67 FOXM1 IGF1R 
 
BP  
normal:raised 
 
 
2.42±0.57:2.30±0.30 
p = 0.84 
 
1.71±0.37:1.46±0.15 
p = 0.77 
 
2.83±1.15:2.94±0.96 
p = 0.51 
 
Fasting plasma 
glucose   
normal:raised 
 
 
2.21±0.47:2.39±0.33 
p = 0.99 
 
1.38±0.32:1.61±0.17 
p = 0.49 
 
3.25±1.13:2.75±0.96 
p = 0.77 
 
Triglycerides 
normal:raised 
 
 
2.48±0.48:2.16±0.38 
p = 0.56 
 
1.70±0.22:1.34±0.21 
p = 0.23 
 
3.70±1.25:1.93:0.56 
p = 0.11 
 
HDL 
normal:low 
 
 
1.89±0.34:2.70±0.39 
p = 0.13 
 
1.27±0.18:1.76±0.22 
p = 0.11 
 
2.12±0.68:3.55±1.23 
p = 0.28 
 
Central obesity 
absent:present 
 
 
2.39±0.42:2.30±0.36 
p = 0.87 
 
1.51±0.26:1.56±0.19 
p = 0.86 
 
1.93±0.72:3.36±1.15 
p = 0.12 
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The percentage of the peri-tumoral area stained for the IL-6 marker assessed at two 
different distances from the tumor was not significantly different between patients with or 
without high fasting plasma glucose, high BP or raised triglycerides, both for pancreatic and 
gastrointestinal NETs (Table 9 and Table 10). 
Table 9- Percentage of the peri-tumoral area stained by the immunohistochemical marker 
IL-6 (mean±s.e.m.) at two different distances from pancreatic NETs. 
MS 
Components 
IL-6 (≤5mm) IL-6 (>5mm) 
 
BP  
normal:raised 
 
 
0.019±0.010:0.022±0.0091 
p = 0.81 
 
 
0.015±0.0036:0.014±0.0067 
p = 0.35 
Fasting plasma 
glucose   
normal:raised 
 
 
0.019±0.010:0.022±0.0090 
p= 0.91 
 
0.014±0.0044:0.015±0.0065 
p = 0.89 
 
Triglycerides 
normal:raised 
 
 
0.019±0.012:0.022±0.0081 
p = 0.84 
 
0.010±0.0047:0.018±0.0060 
p = 0.35 
 
HDL 
normal:low 
 
 
0.024±0.011:0.017±0.0072 
p = 0.84 
 
0.013±0.0038:0.016±0.0077 
p =0.69 
 
Central obesity 
absent:present 
 
 
0.022±0.013:0.016±0.0079 
p = 0.71 
 
0.019±0.0025:0.0078±0.0019 
p = 0.01 
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Table 10 - Percentage of the peri-tumoral area stained by the immunohistochemical marker 
IL-6 (mean±s.e.m.) at two different distances from GI-NETs. 
MS 
Components 
IL-6 (≤5mm) IL-6 (>5mm) 
 
BP  
normal:raised 
 
 
0.022±0.0055:0.026±0.0049 
p = 0.68 
 
0.025±0.0062:0.018±0.0022 
p = 0.60 
Fasting plasma 
glucose   
normal:raised 
 
 
0.025±0.0053:0.024±0.0050 
p = 0.47 
 
0.023±0.0058:0.019±0.0022 
p = 0.77 
 
Triglycerides 
normal:raised 
 
 
0.024±0.0050:0.026±0.0058 
p = 0.75 
 
0.020±0.0026:0.021±0.0044 
p = 0.70 
 
HDL 
normal:low 
 
 
0.018±0.0050:0.030±0.0050 
p = 0.02 
 
0.017±0.0027:0.024±0.0040 
p = 0.17 
 
Central obesity 
absent:present 
 
 
0.019±0.0047:0.029±0.0052 
p = 0.13 
 
0.022±0.0047:0.020±0.0028 
p = 0.96 
 
However, the percentage of the stained peri-tumoral area for IL-6 was statistically 
significantly higher within 5mm from the tumor limit till the end of the tissue in pancreatic 
NETs of patients without central obesity (0.019±0.0025) when compared with patients with 
central obesity (0.0078±0.0019) (p<0.05) (Table 9 and Graph 3).  
 
 
Graph 3- Percentage of the stained peri-tumoral area of GEP-NETs in patients with or 
without central obesity at different distances for the IL-6 protein. 
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In the subset of patients with low HDL, IL-6 percentage of the stained peri-tumoral area at 
5mm distance or less from the tumor limit in gastrointestinal NETs was significantly higher 
(0.030±0.0050) when compared with patients with normal HDL (0.018±0.0050) (p<0.05) 
(Table 10 and Graph 4). 
 
  
Graph 4- Percentage of the stained peri-tumoral area of GEP-NETs in patients with or 
without low HDL at different distances for the IL-6 protein. 
 
4.3- Correlations 
For pancreatic NETs, a statistically significant positive correlation (R2 = 0.648; p< 0.043) 
between the Ki-67 and FOXM1 was found (Graph 5). No other correlations between the 
studied proteins were found to be statistically significant in pancreatic NETs. 
41 
 
 
Graph 5 – Correlation between Ki-67 and FOXM1 proteins in pancreatic NETs. 
For the gastrointestinal NETs, a statistically significantly positive correlation (R2 = 0.673; p< 
0.01) between Ki-67 and FOXM1 was found (Graph 6). 
 
Graph 6- Correlation between Ki-67 and FOXM1 proteins in gastrointestinal NETs. 
In addition, a statistically significantly positive correlation (R2 = 0.624; p< 0.01) between 
IGF1R and FOXM1 was also found (Graph 7). No other correlations between the studied 
proteins were found to be statistically significant in gastrointestinal NETs. 
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Graph 7- Correlating between IGF1R and FOXM1 proteins in gastrointestinal NETs. 
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Chapter 5- Discussion  
The link between MS criteria, its individual parameters and cancer has recently been 
established for different types of cancers. The association of MS with NETs and more 
specifically with GEP-NETs has not been so far reported, although deserves to be explored. 
A possible link between insulin resistance, obesity, MS and GEP-NETs has been 
highlighted, from our previous case control study in which fasting plasma glucose was found 
to be significantly higher in patients harboring GEP-NETs when compared with controls, 
although neither MS criteria nor the reminder of its independent parameters were 
significantly different between the two groups (Santos et al., 2016). Furthermore, our 
subsequent studies between MS and GEP-NETs revealed more relevant associations 
between MS criteria, its individual parameters and GEP-NETs. These clinical results 
revealed that fasting plasma glucose, waist circumference, triglycerides and MS proportion 
were found to be significantly higher in patients with GEP-NETs when compared with 
controls whereas HDL was also significantly lower in patients with GEP-NETs (unpublished 
data). It was also found that elevated waist circumference, fasting plasma glucose, 
triglycerides and MS were risk factors for well-differentiated digestive NETs (unpublished 
data). Thus, the main aim of the research herein described was to gain further insight on 
the molecular links underlying the possible association between GEP-NETs and MS criteria 
and its individual parameters. 
This study focused in evaluating how the expression of molecular markers that participate 
in metabolic and inflammatory pathways, in GEP-NETs and their surrounding tissue, 
correlates with the tumor clinical and pathologic features and presence of MS parameters.   
To achieve this objective the selected molecules were Ki-67, FOXM1 and IGF1R as 
markers of the molecular pathways involved GEP-NETs biology and, IL-6 as inflammation 
marker in the peri-tumoral area.  
The Ki-67 is a well-known protein that is present in all active phases of cell cycle and thus 
infer about the rate of cell growth/proliferation, therefore its expression is closely connected 
to cell proliferation and is routinely used as cell proliferation marker (Scholzen & Gerdes, 
2000). In GEP-NETs, Ki-67 proliferation index is used to attribute the grade and 
classification of these tumors once their biological behavior is dependent on the degree of 
proliferation.  
FOXM1 is an essential transcription factor that has been associated with a major role in cell 
proliferation, differentiation, cell cycle progression, tumorigenesis among others biological 
processes and its overexpression is essential in neoplastic cells of the majority of human 
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solid cancers, including GEP-NETs (Briest et al., 2015; Gomes, Zhao, & Lam, 2013; Halasi 
& Gartel, 2013).The overexpression of this crucial oncogenic transcription factor promotes 
resistance to chemotherapy and other genotoxic drugs of several human cancers leading 
to cancer cell growth and survival (Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 2013; 
Halasi & Gartel, 2013). FOXM1 belongs to the PI3K-Akt-FOXO pathway, where it is an 
important downstream player of this cascade that can be repressed by wild type p53 or 
FOXO3a. This pathway is commonly deregulated in gastrointestinal NETs (Briest et al., 
2015; Gomes, Zhao, & Lam, 2013; Halasi & Gartel, 2013; Wierstra, 2013). MAPK and PI3K 
pathways, the most frequently deregulated pathways in cancer, establish a crosstalk with 
FOXM1 that is also a transcriptional target of STAT3 (Halasi & Gartel, 2013; Wierstra, 
2013). 
IGF1 can be a major autocrine regulator of neuroendocrine tumor growth and secretion 
through the activation of complex molecular networks and IGF1R is one of the crucial TKRs 
in GEP-NETs biology (Briest & Grabowski, 2014; Raymond et al., 2011). Neuroendocrine 
cells that secrete a large amount of IGF-1, lead to IGF1R activation and consequently to a 
high expression of these TKRs and its ligand (Briest & Grabowski, 2014). IGF-1 and insulin 
are weak activators of MAPK pathway but strong activators of the PI3K-Akt-mTOR pathway 
(Raymond et al., 2011). So, IGF1 and IGF1R are highly activated in GEP-NETs and both 
IGF1 and IGF1 receptor are potential molecular targets for a variety of therapies in GEP-
NETs. Nowadays, selective tyrosine kinase inhibitors and monoclonal antibodies are under 
clinical study and these results will help understand if IGF1R is or not a potential clinical 
target (Barbieri et al., 2014). 
In the present study Ki-67, FOXM1 and IGF1R expression in pancreatic and gastrointestinal 
NETs was not significantly different between patients with or without MS or any of MS 
individual parameters (high BP, high fasting plasma glucose, high triglycerides, central 
obesity and low HDL). Notwithstanding the lack of epidemiological evidence disclosing the 
association between MS and GEP-NETs, the previously reported association between 
fasting plasma glucose and digestive neuroendocrine tumors and the increased risk for 
other cancers in patients with MS parameters it was expected that the expression of these 
markers could be altered in patients with at least some of the MS parameters in GEP-NETs 
(Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012; Lin, Ness-Jensen, Hveem, Lagergren, 
& Lu, 2015; Pothiwala, Jain, & Yaturu, 2009; “UMIB Summit 2015", 2016). However, our 
results showed that the presence of MS or any of its individual parameters do not 
significantly influence any of the studied markers in GEP-NETs. Nevertheless, a significant 
positive correlation between the Ki-67 and FOXM1 expression in pancreatic and 
gastrointestinal NETs was found. Knowing the important role of FOXM1 in cell cycle 
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progression and cell proliferation, this correlation suggest that FOXM1 and its pathway 
might be involved and responsible for cell proliferation in GEP-NETs. Moreover, this 
correlation was also previously reported in other study with gastrointestinal NETs (Briest et 
al., 2015). Therefore, inhibition of FOXM1 could be an important molecular target for GEP-
NETs treatment, achievable either by a direct inhibition of FOXM1 protein or by an indirect 
inhibition of FOXM1 through the inhibition of some other player of the PI3K-Akt-FOXO 
pathway or other related in the PI3K, MAPK or STAT3 pathways (Briest et al., 2015; Gomes, 
Zhao, & Lam, 2013 Wierstra, 2013). Despite this and other previous study having 
demonstrated an increase of apoptosis in vitro, in a GEP-NETs cell line, after FOXM1 
inhibition, further studies are needed before its applicability in the routine clinical practice 
(Bhat, Zipfel, Tyler, & Gartel, 2008; Briest et al., 2015). In addition, FOXM1 and IGF1R 
expression were also found to be positively correlated in gastrointestinal NETs. This 
correlation suggests that FOXM1 expression could be stimulated and activated by IGF1R 
activity or vice-versa in gastrointestinal NETs and thereby this could be an additional 
treatment target. Besides that, IGF1 are strong activators of the PI3K-Akt-mTOR pathway 
and a study in cardiomyocytes showed that a downregulated FOXM1 expression is 
associated with a downregulated IGF1R expression (Briest & Grabowski, 2014; Sengupta, 
Kalinichenko, & Yutzey, 2012). In NETs, IGF1 and IGF1R are highly expressed and 
probably can lead to the expression of FOXM1, likely due to the activation of the PI3K-Akt-
FOXO pathway (Briest & Grabowski, 2014; Furukawa et al., 2005).  
Il-6 is a pro-inflammatory cytokine involved mainly in a chronic inflammatory environment 
(Briest & Grabowski, 2014). IL-6 is responsible for shaping the tumor microenvironment as 
one of the most expressed cytokines in the tumor surrounding tissues (Briest & Grabowski, 
2014). Usually, IL-6 tips the balance into pro-inflammatory activity and thus initiation of 
chronic inflammation, resulting in a support to tumor growth and progression via the 
stimulation of different pathways and several downstream effectors (Briest & Grabowski, 
2014).  
Although there is not a clear definition for peri-tumor area, as previous studies have used a 
wide range of distances from the tumor limit as adjacent tumor tissue, spanning from a few 
millimeters to 2 cm wide (Balsat et al., 2013; Zhuang et al., 2013). We have selected the 
maximum distance of 5mm from the tumor limits, whenever available, as definition of peri-
tumoral tissue to study the IL-6 expression and its variation within this and outside of this 
distance to evaluate the inflammatory tonus in the tumor microenvironment, based in 
previous studies for other markers described in the literature (Balsat et al., 2013; Zhuang et 
al., 2013).  
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IL-6 expression in the peri-tumoral tissue was not found to be significantly different between 
patients with and without MS in GEP-NETs, both within the 5mm or less from the tumor limit 
and 5mm or higher till the tissue limit. Admitting that MS is associated with a chronic low 
grade inflammatory state, IL-6 expression was expected to be higher in GEP-NETs patients 
with MS, however our results do not favor that IL-6 exerts an influence in GEP-NETs pro-
inflammatory microenvironment. It was expected for IL-6 expression in the peri-tumoral to 
be higher in patients with at least one of MS individual components, as each one of these 
parameters have been individually linked with inflammation. In fact, high blood pressure 
could be a stimulus for inflammation, high triglycerides levels increase inflammation by the 
activation of Nf-KB pathway and insulin resistance is associated with a chronic low grade 
inflammatory state (Chae, Lee, Rifai, & Ridker, 2001; Welty, 2013; Zeyda & Stulnig, 2009). 
Despite this, IL-6 expression was not significantly different between patients with or without 
high fasting plasma glucose, high BP or raised triglycerides, both for pancreatic and 
gastrointestinal NETs. Thus, suggesting that none of these parameters contributes to the 
inflammation in the tumor microenvironment or that it does not influences IL-6 expression. 
Furthermore, IL-6 expression at the peri-tumoral area in pancreatic NETs was lower in 
patients with central obesity, which is contradictory with what was previously described in 
the literature once obesity is consistently associated with a chronic low grade inflammatory 
state (Zeyda & Stulnig, 2009). Moreover, IL-6 expression in the peri-tumoral area of 
gastrointestinal NETs was significantly higher in patients with low HDL when compared with 
samples of patients with normal HDL, suggesting that low HDL in gastrointestinal NETs 
contributes to an inflammatory environment in the peri-tumoral area, unsurprisingly as HDL 
anti-inflammatory properties have been extensively described before (Welty, 2013). 
In short, knowing the important role of FOXM1 in cell cycle progression and cell proliferation 
FOXM1 could be an important molecular target for GEP-NETs therapy, due to a positive 
correlation with Ki-67, and in gastrointestinal NETs, due to a positive correlation with IGF1R, 
FOXM1 activity might be activated by the expression of IGF1R, likely due to the activation 
of the PI3K-Akt-FOXO pathway.  
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Chapter 6- Conclusion  
The present study has shown that Ki-67, FOXM1 and IGF1R expression in pancreatic and 
gastrointestinal NETs was not significantly different between patients with or without MS or 
any of MS individual parameters (high BP, high fasting plasma glucose, high triglycerides, 
central obesity and low HDL). It was observed a significant positive correlation between the 
Ki-67 and FOXM1 expression in pancreatic and gastrointestinal NETs. It was also observed 
a significant positive correlation between the FOXM1 and IGF1R expression in 
gastrointestinal NETs. IL-6 expression in the peri-tumoral tissue was not found to be 
significantly different between patients with or without MS or some MS individual 
parameters (high fasting plasma glucose, high BP or raised triglycerides) in GEP-NETs, 
both within the 5mm or less from the tumor limit and 5mm or higher till the tissue limit. On 
the other hand, IL-6 expression at the peri-tumoral area in pancreatic NETs was lower in 
patients with central obesity and IL-6 expression in the peri-tumoral area of gastrointestinal 
NETs was significantly higher in patients with low HDL when compared with samples of 
patients with normal HDL. 
These results suggest that the presence of MS or any of its individual parameters do not 
significantly influence any of the studied markers and thus related pathways in GEP-NETs, 
except for IL-6 in two of its individual parameters. For IL-6 expression at the peri-tumoral 
area of gastrointestinal NETs the results suggest that low HDL in gastrointestinal NETs 
contributes to an inflammatory environment in the peri-tumoral area. Contrariwise, for IL-6 
expression at the peri-tumoral area in pancreatic NETs the results suggest a lower 
expression with central obesity, which is contradictory with what was previously described 
in the literature. At last but not least, the results suggest that FOXM1 and its pathway might 
be involved and responsible for cell proliferation in GEP-NETs and thus inhibition of FOXM1 
could be an important molecular target for GEP-NETs treatment. Furthermore, the results 
suggest that FOXM1 expression are related to IGF1R in gastrointestinal NETs and thereby 
this could be an additional treatment target. 
Futures studies will be required in order to understand the link and influence of MS criteria, 
its individual parameters with NETs, more specifically with GEP-NETS. For this, some 
markers and pathways associated with GEP-NETs biology, such as vascular endothelial 
growth factor, C-X-C chemokine receptor type 4, epidermal growth factor, players involved 
in PI3K and MAPK pathways, Nf-KB pathway and other cytokines, could be studied. 
Moreover, studies will also be required to obtain a proper understanding of FOXM1 
protein/pathway role and the consequences of its inhibition in GEP-NETs in order to assess 
its applicability in the routine clinical practice. Finally, a study of IGF1R and FOXM1 
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interaction is needed in gastrointestinal NETs to understand the potential of this possible 
additional treatment target. 
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